Goldplat CEO Werner Klingenberg discusses dividend policy, share buybacks and the Kilimenpesa sale. Watch the full video here.
I believe that we may hear something about the Volchentundra license as well. The Rosgeo JV came out of nowhere, and I'm sure the board will have been considering all assets surrounding MT, especially those in which it has already carried out exploration work & due dilligence in the past. The final pieces of the jigsaw may prove to be the WK flanks & Volchentundra license, before the final big reveal.
Interesting to see that Kaz Minerals has seen its initial takeover offer rise from 640p per share in October to 869p per share today.
I imagine a lot of the same is going on in the background, although we don't have a clue because of the NDAs at Monchetundra. Copper prices have risen steadily since October, but with Palladium reaching $2600 again our PGM basket has outperformed.
Any further length in the process at this point is likely down to significantly higher revised offers, especially if they are coming from bidders that experiencing on-going mining issues.
Could you put me down for 19th December please? I think we'll get the DFS & confirmation of recommended cash offer for the full company bundled together. If it was only Moncehtundra being sold, I don't think it would have taken this long. Surging platinum & rhodium prices make West Kytlim a very attractive asset to own as well.
Thanks and GLA!
"The Definitive Feasibility Study (DFS) commissioned to GIP (designed to upgrade all resources identified on the West Kytlim mining license to mineable categories) has now been submitted for approval to Rosnedra (Russian state agency for subsoil use) in Moscow. Assigning all resources to mineable categories removes the bottleneck in the permitting process, which had restricted building out the mine to full capacity and is designed to improve the project's development and value. On approval West Kytlim will contain the largest soft rock PGM resource globally. The DFS will allow concurrent mining of several areas, which is expected to increase production while also eliminating single asset risk. The Company has sufficient funds to launch mining at several pits at once. More updates will be provided regarding the DFS in due course."
From the interims at the end of September, surely can't be too far off from the final DFS approval now. Would love to see an update on the rhodium we have in the ground in addition to all the palladium, platinum, iridium and gold!
If you take a look at page 19 on the investor presentation (https://www.eurasiamining.co.uk/investors/presentations) you will see the total target resource in the license area (after flanks approval) is 22.6Moz. If you add the total resource in the Monchegorsky region you're looking at an additional 17.7Moz, which is where the 40Moz figure comes from.
The resource is 64% Palladium, the rest Platinum, so if we take current Palladium prices per ounce $2325 and multiply this by 14.5Moz + Plaintum at $950 per ounce multiplied by 8.1Moz = $41.4 billion in situ value for MT alone.
Well spotted by Frances Clarke on Twitter, NN managed to expand their syndicate facility agreement to $4.15 billion in Feb this year. They will have no issues paying top dollar for a top-class asset like MT.
Hi all, hope you are enjoying your weekend roasts & rums! This is my first post on here, I've been doing some research into REE's in the Kola Peninsula and I think the potential of this has been underestimated by the market. I've attached some links below for anyone interested in doing some more reading, but the Kola Peninsula seems to be an extraordinarily unique resource-rich region, with more or less everything a mining giant would ever want!
A world-class PGM asset, which also contains plenty of base metals & critical Rare Earth Elements could lead to an offer price that beats most of our expectations. GLA, fingers crossed for an announcement next week!
Brilliant AGM thread from Tay on Twitter, summarising some key points from yesterday.
Fantastic news on the NPT government contract. Can definitely see this being rolled out across airports in the coming weeks! Just also wanted to add that this has really been one of the most informative boards I have come across. So a big thank you to all for the excellent research and continued contributions. Looking forward to tomorrow! GLA
Just seen a new £633 million tender for Covid-19 related services on bidstats. The tender " shall recruit on average approximately 30,000 participants per month throughout the period until May 2022. During this time, the number of active participants will typically be approximately 450,000, although we will only be testing at peak effort approximately 100,000 a week. All participants shall be swab tested and up to 20% of participants shall also receive blood tests for antibodies."
Perfect timing for the launch of our antibody test imo.
Just a reminder that we not only have the launch of the antibody test to look forward to by month's end, but also the results for the Care Home Trials. Study completion date on 28th September to evaluate the effectiveness of our Nasal Swabs & Near Patient Testing system.
We already have Pathflow Devices for Influenza A&B and RSV. It's highly unlikely that that resources haven't been dedicated to implementing the same style test for Covid-19. 15 minute tests would be a game changer and put us in a position where our product portfolio would meet every kind of testing need for the market. We will essentially become a one-stop shop for all testing requirements for Covid-19.
Good morning all, just wanted to recap what news we might be expecting to hear about in the coming weeks. Please feel free to add to this if I've missed anything!
- Sales update (potentially a product & regional sales update too).
- Possible UK tender award, or extension of current PHE contract.
- Other possible new contract awards (especially in new markets using 2 gene test).
- An update on US sales and possibly our strategic US partner?
- Regulatory update to summarise all new regions where we have won approval for our products.
- News from the Care Home Trials using our NPT testing system (expected by the end of this month).
- An expanded capacity announcement, including details of how any Winterplex tests we will be able to produce.
- The release of our antibody test and details of who we are partnering on this project.
- New R&D projects (rumoured Nucleic Acid Amplification Technology, faster tests).
- Potential acquisitions, which might make sense given the new visibility over the demand for testing.
- A 3-year plan update of some kind. Graham keeps on re-iterating that we are well on track to become a mid-cap company, but it would be great to see a more elaborate plan of how we are going to get there.
Great update today, the company has done exceptionally well at re-investing capital to develop an R&D stream that will reap rewards for the years to come. I'm sure some non-Covid work is also going on behind the scenes to prepare the company for the future. Even if the company doesn't get bought out, it looks like we could become a serious global leader in the diagnostics & infectious diseases field.
Surely the launch of the winter tests is worthy of an RNS? Looks to be ahead of schedule. Not sure why Twitter has become the primary source of company info.